Distributor inventory | Tablet

Type 2 diabetes mellitus: to improve post-meal and overall blood glucose control when diet and exercise alone are insufficient; used when combination therapy is required.

Voglibose is an alpha-glucosidase inhibitor that delays carbohydrate digestion and absorption in the intestine, reducing post-meal glucose spikes. Repaglinide is a short-acting insulin secretagogue (meglitinide) that stimulates pancreatic insulin release, mainly around meals, thereby lowering postprandial blood glucose.

Oral tablet. Take exactly as prescribed. Typically taken before meals (repaglinide is usually taken 15–30 minutes before each main meal; skip the dose if you skip a meal). Voglibose is usually taken just before/with the first bite of meal. Follow your doctor’s instructions for this fixed-dose combination; monitor blood glucose regularly.

Hypoglycaemia, abdominal pain, flatulence, diarrhoea, nausea, headache, dizziness, increased liver enzymes

Risk of hypoglycaemia (higher with missed meals, excessive exercise, alcohol, or with other antidiabetics); do not take repaglinide component if a meal is skipped. Use caution in hepatic impairment; monitor liver function if advised. Use with caution in renal impairment and in elderly. Voglibose may cause GI symptoms (gas/diarrhoea). Not for type 1 diabetes or diabetic ketoacidosis. Inform doctor about frequent hypoglycaemia, irregular meals, or planned surgery/acute illness.

Gemfibrozil (contraindicated/avoid; markedly increases repaglinide levels), Clarithromycin, Azole antifungals (e.g., itraconazole), Rifampicin (reduces effect), Cyclosporine, Other antidiabetic medicines/insulin (increased hypoglycaemia risk), Beta-blockers (may mask hypoglycaemia symptoms), Alcohol (increases hypoglycaemia risk)

Store below 25°C in a dry place. Protect from moisture and light. Keep out of reach of children.

Prandial R 0.2/0.5 Tablet, Vogli-R 0.2/0.5 Tablet, Repag-V 0.2/0.5 Tablet, Voglibose 0.2 mg + Repaglinide 0.5 mg Tablets (generic equivalents)